期刊
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
卷 34, 期 7, 页码 524-527出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MPH.0b013e31826b9d25
关键词
sarcoma; gemcitabine; docetaxel; bevacizumab
Background: The outcome for patients with relapsed and refractory pediatric sarcomas remains dismal. Novel agents are needed to improve overall survival in these patients. Observations: We present 3 patients with relapsed/refractory sarcomas treated with gemcitabine, docetaxel, and bevacizumab in 3-week cycles. The combination was well tolerated with minimal toxicity. Two patients had a partial response and the third patient had stable disease for >6 months. Conclusions: These results are limited by small patient numbers but this strategy should be evaluated in prospective clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据